Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.42 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 14/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | TACR3 | P29371 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4637956 | 0.89 | ALDH1A1 (0.46) | TACR1EPAS1GPBAR1GRM2 | |
| SCHEMBL4638855 | 0.87 | EPAS1 (0.50) | TACR1EPAS1GPBAR1GRM2 | |
| SCHEMBL14144832 | 0.84 | TACR1 (0.37) | TACR1EPAS1GPBAR1TACR3 | |
| SCHEMBL4639409 | 0.84 | TACR1 (0.39) | TACR1EPAS1GPBAR1GRM2 | |
| SCHEMBL14587205 | 0.83 | TGM2 (0.44) | TACR1EPAS1GPBAR1 | |
| SCHEMBL4638510 | 0.78 | USP2 (0.40) | TACR1EPAS1GPBAR1GRM2 | |
| SCHEMBL5797524 | 0.77 | ALDH1A1 (0.50) | TACR1GPBAR1GRM2 | |
| SCHEMBL4707134 | 0.77 | EPAS1 (0.40) | TACR1EPAS1GPBAR1GRM2 | |
| SCHEMBL4705059 | 0.77 | TACR1 (0.36) | TACR1EPAS1GPBAR1GRM2 | |
| SCHEMBL4707969 | 0.77 | CDC7 (0.42) | TACR1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501808-B1 | TACHYKININ RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-07-02 | — | — | EP | disclosed |
| US-7179804-B2 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-02-20 | — | — | US | disclosed |
| US-20050239776-A1 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 2005-10-27 | — | — | US | disclosed |
| EP-1501808-A1 | TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003091227-A1 | TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239776-A1 | Tachykinin receptor antagonists | TACR2, TACR1, PROKR1 | TACR1 2/4885EPAS1 2885/4885GPBAR1 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.